- Home
- PRSO vs QLGN Comparison
PRSO vs QLGN Comparison
Compare PRSO & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- QLGN
- Stock Information
- Founded
- PRSO 2008
- QLGN 1996
- Country
- PRSO United States
- QLGN United States
- Employees
- PRSO N/A
- QLGN N/A
- Industry
- PRSO Semiconductors
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- QLGN Health Care
- Exchange
- PRSO Nasdaq
- QLGN Nasdaq
- Market Cap
- PRSO 4.2M
- QLGN 3.4M
- IPO Year
- PRSO 2001
- QLGN N/A
- Fundamental
- Price
- PRSO $1.04
- QLGN $4.18
- Analyst Decision
- PRSO Strong Buy
- QLGN
- Analyst Count
- PRSO 2
- QLGN 0
- Target Price
- PRSO $3.38
- QLGN N/A
- AVG Volume (30 Days)
- PRSO 125.2K
- QLGN 54.9K
- Earning Date
- PRSO 11-12-2024
- QLGN 11-14-2024
- Dividend Yield
- PRSO N/A
- QLGN N/A
- EPS Growth
- PRSO N/A
- QLGN N/A
- EPS
- PRSO N/A
- QLGN N/A
- Revenue
- PRSO $12,728,000.00
- QLGN N/A
- Revenue This Year
- PRSO $9.59
- QLGN N/A
- Revenue Next Year
- PRSO $1.63
- QLGN N/A
- P/E Ratio
- PRSO N/A
- QLGN N/A
- Revenue Growth
- PRSO N/A
- QLGN N/A
- 52 Week Low
- PRSO $0.73
- QLGN $3.34
- 52 Week High
- PRSO $11.20
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- PRSO 55.90
- QLGN 43.01
- Support Level
- PRSO $0.80
- QLGN $3.53
- Resistance Level
- PRSO $1.12
- QLGN $4.39
- Average True Range (ATR)
- PRSO 0.09
- QLGN 0.33
- MACD
- PRSO 0.05
- QLGN 0.06
- Stochastic Oscillator
- PRSO 88.69
- QLGN 50.98
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.